{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:23:32Z","timestamp":1791149012986,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,7,25]],"date-time":"2014-07-25T00:00:00Z","timestamp":1406246400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s11523-014-0328-7","type":"journal-article","created":{"date-parts":[[2014,7,24]],"date-time":"2014-07-24T01:32:57Z","timestamp":1406165577000},"page":"229-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports"],"prefix":"10.1007","volume":"10","author":[{"given":"Adeline","family":"Egron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Olivier-Abbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Gouraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Babai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Combret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bondon-Guitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,25]]},"reference":[{"key":"328_CR1","unstructured":"Castot A, Haramburu F, Kreft-Ja\u00efs C (2008) Hospitalisations dues aux effets ind\u00e9sirables des m\u00e9dicaments: r\u00e9sultats d\u2019une \u00e9tude nationale Point sur la nouvelle campagne d\u2019information sur les traitements anticoagulants antivitamine K. http:\/\/www.sante.gouv.fr\/IMG\/pdf\/EMIR.pdf"},{"key":"328_CR2","first-page":"626","volume":"12","author":"PM Lau","year":"2004","unstructured":"Lau PM, Stewart K, Dooley M (2004) The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer 12:626\u2013633. doi: 10.1007\/s00520-004-0622-5","journal-title":"Support Care Cancer"},{"key":"328_CR3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2165\/11536800-000000000-00000","volume":"33","author":"LHF Hoonhout","year":"2010","unstructured":"Hoonhout LHF, de Bruijne MC, Wagner C et al (2010) Nature, occurrence and consequences of medication-related adverse events during hospitalization: a retrospective chart review in the Netherlands. Drug Saf 33:853\u2013864. doi: 10.2165\/11536800-000000000-00000","journal-title":"Drug Saf"},{"key":"328_CR4","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1200\/JCO.2009.27.6626","volume":"28","author":"DLB Schwappach","year":"2010","unstructured":"Schwappach DLB, Wernli M (2010) Chemotherapy patients\u2019 perceptions of drug administration safety. J Clin Oncol 28:2896\u20132901. doi: 10.1200\/JCO.2009.27.6626","journal-title":"J Clin Oncol"},{"key":"328_CR5","unstructured":"Faye E, Bondon-Guitton E, Olivier-Abbal P, Bagheri H, Montastruc JL and The French Association of Regional Pharmacovigilance Centres (2011) \u201cSerious\u201d cutaneous reactions with protein kinase inhibitors. In: 15\u00e8me congr\u00e8s de le Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et de Th\u00e9rapeutique 22\u201324 March 2011; Grenoble; France"},{"key":"328_CR6","author":"E Faye","year":"2013","unstructured":"Faye E, Bondon-Guitton E, Olivier-Abbal P et al (2013) Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors. Eur J Clin Pharmacol. doi: 10.1007\/s00228-013-1532-6","journal-title":"Eur J Clin Pharmacol"},{"key":"328_CR7","unstructured":"Bowlin SJ (2012) Surveillance of drug metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral antineoplastic agents. In: 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 16 March 2012; Washington, Maryland, USA"},{"key":"328_CR8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1246-7820(99)80036-6","volume":"6","author":"A Spreux","year":"1999","unstructured":"Spreux A, Baldin B, Chichmanian RM (1999) Pharmacovigilance in practice. Transfus Clin Biol 6:254\u2013259","journal-title":"Transfus Clin Biol"},{"key":"328_CR9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jbspin.2006.09.002","volume":"73","author":"J-L Montastruc","year":"2006","unstructured":"Montastruc J-L, Sommet A, Lacroix I et al (2006) Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine 73:629\u2013632. doi: 10.1016\/j.jbspin.2006.09.002","journal-title":"Joint Bone Spine"},{"key":"328_CR10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255\u20131259. doi: 10.1016\/S0140-6736(00)02799-9","journal-title":"Lancet"},{"key":"328_CR11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory activities (MedDRA). Drug Saf 20:109\u2013117","journal-title":"Drug Saf"},{"key":"328_CR12","first-page":"111","volume":"40","author":"B B\u00e9gaud","year":"1985","unstructured":"B\u00e9gaud B, Evreux JC, Jouglard J, Lagier G (1985) Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 40:111\u2013118","journal-title":"Therapie"},{"key":"328_CR13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2515\/therapie:2005005","volume":"60","author":"P Olivier","year":"2005","unstructured":"Olivier P, Caron J, Haramburu F et al (2005) Validation of a measurement scale: example of a French Adverse Drug Reactions Preventability Scale. Therapie 60:39\u201345","journal-title":"Therapie"},{"key":"328_CR14","unstructured":"European Medicines Agency (2013) Sprycel\u00ae dasatinib: summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000709\/WC500056998.pdf . Accessed 10 Jan 2014"},{"key":"328_CR15","unstructured":"European Medicines Agency (2014) Glivec\u00ae imatinib: summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000406\/WC500022207.pdf . Accessed 10 Jan 2014"},{"key":"328_CR16","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1248\/bpb.28.1805","volume":"28","author":"T Niwa","year":"2005","unstructured":"Niwa T, Shiraga T, Takagi A (2005) Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28:1805\u20131808","journal-title":"Biol Pharm Bull"},{"key":"328_CR17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2125.1999.00881.x","volume":"47","author":"C Pierfitte","year":"1999","unstructured":"Pierfitte C, B\u00e9gaud B, Lagnaoui R, Moore ND (1999) Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol 47:329\u2013331","journal-title":"Br J Clin Pharmacol"},{"key":"328_CR18","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/sim.1157","volume":"21","author":"PGM Heijden Van der","year":"2002","unstructured":"Van der Heijden PGM, van Puijenbroek EP, van Buuren S, van der Hofstede JW (2002) On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med 21:2027\u20132044. doi: 10.1002\/sim.1157","journal-title":"Stat Med"},{"key":"328_CR19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/11596570-000000000-00000","volume":"35","author":"KM Hakkarainen","year":"2012","unstructured":"Hakkarainen KM, Andersson Sundell K, Petzold M, H\u00e4gg S (2012) Methods for assessing the preventability of adverse drug events: a systematic review. Drug Saf 35:105\u2013126. doi: 10.2165\/11596570-000000000-00000","journal-title":"Drug Saf"},{"key":"328_CR20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jama.1995.03530010043033","volume":"274","author":"DW Bates","year":"1995","unstructured":"Bates DW, Cullen DJ, Laird N et al (1995) Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 274:29\u201334","journal-title":"JAMA"},{"key":"328_CR21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF02600138","volume":"8","author":"DW Bates","year":"1993","unstructured":"Bates DW, Leape LL, Petrycki S (1993) Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 8:289\u2013294","journal-title":"J Gen Intern Med"},{"key":"328_CR22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2190\/9AJD-664C-00EG-8X3L","volume":"30","author":"EJ Thomas","year":"2000","unstructured":"Thomas EJ, Orav EJ, Brennan TA (2000) Hospital ownership and preventable adverse events. Int J Health Serv 30:745\u2013761","journal-title":"Int J Health Serv"},{"key":"328_CR23","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJMsa020703","volume":"348","author":"TK Gandhi","year":"2003","unstructured":"Gandhi TK, Weingart SN, Borus J et al (2003) Adverse drug events in ambulatory care. N Engl J Med 348:1556\u20131564. doi: 10.1056\/NEJMsa020703","journal-title":"N Engl J Med"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-014-0328-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-014-0328-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-014-0328-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T16:15:13Z","timestamp":1559405713000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-014-0328-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,25]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["328"],"URL":"https:\/\/doi.org\/10.1007\/s11523-014-0328-7","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,25]]}}}